Home/Pipeline/GRAdHIVNE1

GRAdHIVNE1

HIV Prevention

Phase 1Active

Key Facts

Indication
HIV Prevention
Phase
Phase 1
Status
Active
Company

About ReiThera

ReiThera is a dual-focus Italian biotech, functioning both as a specialized CDMO for viral vectors and as a developer of its own therapeutic candidates. Its core expertise lies in viral vector engineering and scalable GMP manufacturing for adenoviruses, AAV, Lentivirus, MVA, and Herpes Simplex vectors. The company is advancing a clinical-stage HIV vaccine candidate in partnership with major research institutes and is actively involved in outbreak response efforts, such as for Marburg virus, while serving a global client base from its state-of-the-art facility in Rome.

View full company profile

Other HIV Prevention Drugs

DrugCompanyPhase
Cabotegravir (LA) for PrEPViiV HealthcareApproved/Phase 3
srRNA Vaccine for HIVReplicate BiosciencePre-clinical